Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention

Nanomedicine

Volumn 9, Issue 11, 2014, Pages 1595-1612

  Meng, Jianing ^a   Zhang, Tao ^a   Agrahari, Vivek ^a   Ezoulin, Miezan J ^a   Youan, Bi Botti C ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

HIV prevention; mucoadhesion; nanoparticle; tenofovir; thiolated chitosan; vaginal drug delivery

Indexed keywords

CAVEOLIN; CHITOSAN; NANOPARTICLE; TENOFOVIR; THIOGLYCOLIC ACID; 2-MERCAPTOACETATE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; THIOGLYCOLIC ACID DERIVATIVE; THIOL DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BIOPHYSICS; CELL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; DYNAMIC LIGHT SCATTERING; FEMALE; FLUOROMETRY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGHT SCATTERING; MUCOADHESION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SWINE; ULTRAVIOLET SPECTROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMISTRY; DRUG DELIVERY SYSTEM; HIV INFECTIONS; HUMAN; NANOMEDICINE; PH; PIG; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ADENINE; ANIMALS; ANTI-HIV AGENTS; CAVEOLINS; CELL LINE; CHITOSAN; DRUG DELIVERY SYSTEMS; FLUOROMETRY; HIV INFECTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOMEDICINE; NANOPARTICLES; ORGANOPHOSPHONATES; SULFHYDRYL COMPOUNDS; SWINE; TENOFOVIR; THIOGLYCOLATES;

EID: 84908879621     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.136     Document Type: Article

References (75)

1. Hackley VA, Ferraris CF. The Use of Nomenclature in Dispersion Science and Technology. NIST Recommended Practice Guide. National Institute of Standards and Technology, Washington DC, USA (2001).
2. UNAIDS. Introduction. In: Global Report UNAIDS Report on the Global AIDS Epidemic 2013. UNAIDS, Geneva, Switzerland, 4-11 (2013).
3. Krishnan S, Dunbar MS, Minnis AM, Medlin CA, Gerdts CE, Padian NS. Poverty, gender inequities, and women's risk of human immunodeficiency virus/AIDS. Ann. NY Acad. Sci. 1136, 101-110 (2008).
4. UNAIDS. Eliminate gender inequalities and gender-based abuse and violence and increase thecapacity of women and girls to protect themselves from HIV. In: Global Report UNAIDS Report on the Global AIDS Epidemic 2013. UNAIDS, Geneva, Switzerland, 78-83 (2013).
5. Askew I, Berer M. The contribution of sexual and reproductive health services to the fight against HIV/AIDS: a review. Reprod. Health Matt. 11 (22), 51-73 (2003).
6. Weber J, Desai K, Darbyshire J. The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med. 2 (5), e142 (2005).
7. Ndesendo VM, Pillay V, Choonara YE, Buchmann E, Bayever DN, Meyer LC. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 9 (2), 505-520 (2008).
8. Mamo T, Moseman EA, Kolishetti N et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond.) 5 (2), 269-285 (2010).
9. Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur. J. Pharm. Biopharm. 79 (3), 526-536 (2011).
10. Alukda D, Sturgis T, Youan BB. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J. Pharm. Sci. 100 (8), 3345-3356 (2011).
11. Sosnik A. Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a dual scientific and ethical challenge and a still pending agenda. Nanomedicine (Lond.) 5 (6), 833-837 (2010).
12. Murugeshu A, Astete C, Leonardi C, Morgan T, Sabliov CM. Chitosan/PLGA particles for controlled release of alpha-tocopherol in the GI tract via oral administration. Nanomedicine (Lond.) 6 (9), 1513-1528 (2011).
13. Roldo M, Hornof M, Caliceti P, Bernkop-Schnurch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur. J. Pharm. Biopharm. 57 (1), 115-121 (2004).
14. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57 (11), 1569-1582 (2005).
15. Leitner VM, Walker GF, Bernkop-Schnurch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur. J. Pharm. Biopharm. 56 (2), 207-214 (2003).
16. Meng J, Sturgis TF, Youan BB. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur. J. Pharm. Sci. 44 (1-2), 57-67 (2011).
17. Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann. Pharmacother. 37 (6), 849-859 (2003).
18. Jang KI, Lee HG. Stability of chitosan nanoparticles for l-ascorbic acid during heat treatment in aqueous solution. J. Agric. Food Chem. 56 (6), 1936-1941 (2008).
19. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 16 (10), 1576-1581 (1999).
20. Thongborisute J, Takeuchi H, Yamamoto H, Kawashima Y. Visualization of the penetrative and mucoadhesive properties of chitosan and chitosan-coated liposomes through the rat intestine. J. Liposome Res. 16 (2), 127-141 (2006).
21. Ma Z, Lim LY. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 20 (11), 1812-1819 (2003).
22. Kätzel U, Vorbau M, Stintz M, Gottschalk-Gaudig T, Barthel H. Dynamic light scattering for the characterization of polydisperse fractal systems: II. Relation between structure and DLS results. Part. Syst. Charact. 25, 19-30 (2008).
23. Sassi AB, Isaacs CE, Moncla BJ, Gupta P, Hillier SL, Rohan LC. Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J. Pharm. Sci. 97 (8), 3123-3139 (2008).
24. Don TM, Hsu SH, Chiu WY. Structures and thermal properties of chitosan-modified poly(methyl methacrylate). J. Polym. Sci. 39, 1646-1655 (2001).
25. Nayak AK, Laha B, Sen KK. Development of hydroxyapatite-ciprofloxacin bone-implants using "quality by design". Acta Pharm. 61 (1), 25-36 (2011).
26. Lackman-Smith C, Osterling C, Luckenbaugh K et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52 (5), 1768-1781 (2008).
27. Jorgenson JH, Turnidge JD, Washington JA et al. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Manual of Clinical Microbiology (Seventh Edition). Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (Eds). ASM Press, Washington DC, USA, 1327-1341 (1999).
28. Xie J, Wang CH. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm. Res. 22 (12), 2079-2090 (2005).
29. Pifer MA, Kibuule LK, Maerz T, Studzinski DM, Baker KC, Herkowitz HN. In vitro response of human chondrocytes to a combination of growth factors and a proteinase inhibitor. Orthopedics 35 (1), 35-42 (2012).
30. Douglas KL, Piccirillo CA, Tabrizian M. Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur. J. Pharm. Biopharm. 68 (3), 676-687 (2008).
31. Ranga Rao KV, Buri P. A novel in situ method to test polymers and coated microparticles for bioadhesion. Endocr. Rev. 52 15 (13), 265-270 (1989).
32. Albrecht K, Zirm EJ, Palmberger TF, Schlocker W, Bernkop-Schnurch A. Preparation of thiomer microparticles and in vitro evaluation of parameters influencing their mucoadhesive properties. Drug. Dev. Ind. Pharm. 32 (10), 1149-1157 (2006).
33. Grabovac V, Guggi D, Bernkop-Schnurch A. Comparison of the mucoadhesive properties of various polymers. Adv. Drug Deliv. Rev. 57 (11), 1713-1723 (2005).
34. Dudhania A, Kosaraju S. Bioadhesive chitosan nanoparticles: preparation and characterization. Carbohyd. Polym. 81, 243-251 (2010).
35. Lopes LB, Ferreira DA, De Paula D et al. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm. Res. 23 (6), 1332-1342 (2006).
36. Montgomery D. Response surface methods and design. In: Design and Analysis of Experiments. John Wiley and Sons Inc., NY, USA, 405-458 (1995).
37. Ferreira SL, Bruns RE, Da Silva EG et al. Statistical designs and response surface techniques for the optimization of chromatographic systems. J. Chromatogr. A 1158 (1-2), 2-14 (2007).
38. Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness/ruggedness tests in method validation. J. Pharm. Biomed. Anal. 24 (5-6), 723-753 (2001).
39. Miller JN, Miller JC. Significance tests. In: Statistics and Chemometrics for Analytical Chemistry (Fifth Edition). Pearson Education, NJ, USA, 39-69 (2010).
40. Bei D, Marszalek J, Youan BB. Formulation of dacarbazine-loaded cubosomes-part II: influence of process parameters. AAPS Pharm Sci Tech 10 (3), 1040-1047 (2009).
41. Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study. Chem. Pharm. Bull. (Tokyo) 59 (2), 272-278 (2011).
42. Choi SU, Bui T, Ho RJ. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J. Pharm. Sci. 97 (2), 931-943 (2008).
43. Van Gelder J, Witvrouw M, Pannecouque C et al. Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. Int. J. Pharm. 186 (2), 127-136 (1999).
44. Cleland WW. Dithiothreitol, a new protective reagent for Sh groups. Biochemistry 3, 480-482 (1964).
45. Hu B, Pan C, Sun Y, Hou Z, Ye H, Zeng X. Optimization of fabrication parameters to produce chitosan-tripolyphosphate nanoparticles for delivery of tea catechins. J. Agric. Food. Chem. 56 (16), 7451-7458 (2008).
46. Nasti A, Zaki NM, De Leonardis P et al. Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm. Res. 26 (8), 1918-1930 (2009).
47. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329 (5996), 1168-1174 (2010).
48. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13 (2), 123-133 (2001).
49. Merchant HA, Shoaib HM, Tazeen J, Yousuf R. Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: a technical note. AAPS Pharm Sci Tech 7 (3), 78 (2006).
50. Baloglu E, Senyigit ZA, Karavana SY, Bernkop-Schnurch A. Strategies to prolong the intravaginal residence time of drug delivery systems. J. Pharm. Sci. 12 (3), 312-336 (2009).
51. Lee WA, He GX, Eisenberg E et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 49 (5), 1898-1906 (2005).
52. Uboldi C, Bonacchi D, Lorenzi G et al. Gold nanoparticles induce cytotoxicity in the alveolar type-II cell lines A549 and NCIH441. Part Fibre Toxicol. 6, 18 (2009).
53. Au C, Mutkus L, Dobson A, Riffle J, Lalli J, Aschner M. Effects of nanoparticles on the adhesion and cell viability on astrocytes. Biol. Trace Elem. Res. 120 (1-3), 248-256 (2007).
54. Wilks M, Wiggins R, Whiley A et al. Identification and H2O2 production of vaginal lactobacilli from pregnant women at high risk of preterm birth and relation with outcome. J. Clin. Microbiol. 42 (2), 713-717 (2004).
55. Verhelst R, Verstraelen H, Claeys G et al. Comparison between Gram stain and culture for the characterization of vaginal microflora: definition of a distinct grade that resembles grade I microflora and revised categorization of grade I microflora. BMC Microbiol. 5, 61 (2005).
56. Casella JF, Flanagan MD, Lin S. Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change. Nature 293 (5830), 302-305 (1981).
57. Luxford KA, Murphy CR. Cytoskeletal control of the apical surface transformation of rat uterine epithelium. Biol. Cell 79 (2), 111-116 (1993).
58. Meng H, Yang S, Li Z et al. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano 5 (6), 4434-4447 (2011).
59. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat. Cell Biol. 11 (5), 510-520 (2009).
60. Perumal OP, Inapagolla R, Kannan S, Kannan RM. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials 29 (24-25), 3469-3476 (2008).
61. Pho MT, Ashok A, Atwood WJ. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J. Virol. 74 (5), 2288-2292 (2000).
62. Benmerah A, Lamaze C. Clathrin-coated pits: vive la difference? Traffic 8 (8), 970-982 (2007).
63. Manes S, Del Real G, Martinez AC. Pathogens: raft hijackers. Nat. Rev. Immunol. 3 (7), 557-568 (2003).
64. Rybin VO, Grabham PW, Elouardighi H, Steinberg SF. Caveolae-associated proteins in cardiomyocytes: caveolin-2 expression and interactions with caveolin-3. Am. J. Physiol. Heart Circ. Physiol. 285 (1), H325-H332 (2003).
65. Georgieva JV, Kalicharan D, Couraud PO et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol. Ther. 19 (2), 318-325 (2011).
66. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem. J. 377 (Pt 1), 159-169 (2004).
67. Bathori G, Cervenak L, Karadi I. Caveolae-an alternative endocytotic pathway for targeted drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 21 (2), 67-95 (2004).
68. Peng SF, Tseng MT, Ho YC, Wei MC, Liao ZX, Sung HW. Mechanisms of cellular uptake and intracellular trafficking with chitosan/DNA/poly(gamma-glutamic acid) complexes as a gene delivery vector. Biomaterials 32 (1), 239-248 (2011).
69. Hammes A, Andreassen TK, Spoelgen R et al. Role of endocytosis in cellular uptake of sex steroids. Cell 122 (5), 751-762 (2005).
70. Dekker J, Rossen JW, Buller HA, Einerhand AW. The MUC family: an obituary. Trends Biochem. Sci. 27 (3), 126-131 (2002).
71. Bernkop-Schnurch A, Schwarz V, Steininger S. Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm. Res. 16 (6), 876-881 (1999).
72. Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J. Pharm. Sci. 97 (1), 9-21 (2008).
73. Nicolazzo JA, Reed BL, Finnin BC. The effect of various in vitro conditions on the permeability characteristics of the buccal mucosa. J. Pharm. Sci. 92 (12), 2399-2410 (2003).
74. Lesch CA, Squier CA, Cruchley A, Williams DM, Speight P. The permeability of human oral mucosa and skin to water. J. Dent. Res. 68 (9), 1345-1349 (1989).
75. Bernkop-Schnurch A, Hornof M, Guggi D. Thiolated chitosans. Eur. J. Pharm. Biopharm. 57 (1), 9-17 (2004).